OncoSpherix

OncoSpherix is a pre-clinical stage oncology drug development company located in Atlanta, Ga, United States. The company focuses on advancing a proprietary platform of first-in-class small molecule therapeutics designed to target a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). With several classes of small molecules that block activation of HIF-1 through novel mechanisms, OncoSpherix has demonstrated promising results in mouse models, showing a reduction in primary tumor growth, inhibition of metastases, and prolonged survival across various types of cancer, including glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, and breast cancer. Notably, these agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to enhanced cancer control.

Established in 2018, OncoSpherix recently secured a $2.05M grant investment on 01 April 2023 from the National Institutes of Health. The company operates in the Health Care and Pharmaceutical industries, aiming to develop advanced drugs for advanced cancers, as encapsulated in its slogan "Advanced drugs for advanced cancers."